Oct 29
CBIO · Crescent Biopharma, Inc. · Documents
$13.00
+0.09 (+0.70%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$505.64M
Shares
38.90M
Volume · Nov 20
422.38K
Avg daily vol (3M)
358.97K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2024
Oct 29
Proxy statement
DEFA14A
Proxy statement
Aug 8
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Net loss $10.1M
Diluted EPS -$0.16
Jul 30
Current report
8-K
Events of Jul 24
Exit or restructuring costs, Director or officer change, or executive pay, Regulation FD disclosure
Jun 26
Current report
8-K
Events of Jun 21
Delisting notice or listing transfer
Jun 13
Current report
8-K
Events of Jun 10
Director or officer change, or executive pay
Jun 4
Current report
8-K
Regulation FD disclosure
May 9
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Net loss $10.74M
Diluted EPS -$0.17
May 6
Current report
8-K
Financial results, Regulation FD disclosure
May 2
Current report
8-K
Events of May 1
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
Apr 1
Proxy statement
DEF 14A
Meeting May 1, 2024
Proxy statement
Apr 1
Annual report to holders
ARS
Annual report to holders
Mar 27
Current report
8-K
Financial results
Mar 27
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Revenue $10K
▼ 86.7%
Net loss $36.9M
Diluted EPS -$0.58
Mar 22
Proxy statement
PRE 14A
Meeting May 1, 2024
Proxy statement
Mar 1
Current report
8-K
Regulation FD disclosure
Jan 2
Current report
8-K
Entered into a material agreement
2023
Nov 3
Current report
8-K
Financial results
Nov 3
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Net loss $9.2M
Diluted EPS -$0.14
Aug 2
Current report
8-K
Financial results
Aug 2
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Net loss $8.26M
Diluted EPS -$0.13
May 22
Current report
8-K
Events of May 19
Shareholder vote results
May 3
Current report
8-K
Financial results
May 3
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Net loss $10.36M
Diluted EPS -$0.17
Apr 21
Proxy statement
DEF 14A
Meeting May 19, 2023
Proxy statement
Apr 21
Current report
8-K
Events of Apr 19
Entered into a material agreement
Apr 21
Annual report to holders
ARS
Annual report to holders
Mar 29
Current report
8-K
Financial results
Mar 29
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Revenue $75K
▼ 93.5%
Net loss $46.69M
Diluted EPS -$0.89
Mar 10
Current report
8-K
Regulation FD disclosure
Mar 2
Current report
8-K
Regulation FD disclosure
Feb 21
Current report
8-K
Director or officer change, or executive pay
2022
Nov 9
Current report
8-K
Financial results
Nov 9
Quarterly report
10-Q
FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Net loss $8.52M
Diluted EPS -$0.16
Oct 4
Current report
8-K
Regulation FD disclosure
Aug 3
Current report
8-K
Financial results
Aug 3
Quarterly report
10-Q
FY2022 Q2, ended Jun 30
Quarterly report for FY2022 Q2
Revenue $75K
▲ 52716.9%
Net loss $13.27M
Diluted EPS -$0.25
Jun 3
Current report
8-K
Events of May 31
Delisting notice or listing transfer
May 20
Current report
8-K
Events of May 18
Director or officer change, or executive pay, Shareholder vote results
Apr 28
Current report
8-K
Financial results
Apr 28
Quarterly report
10-Q
FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Net loss $14.65M
Diluted EPS -$0.28
Apr 11
Proxy statement
DEF 14A
Meeting May 18, 2022
Proxy statement
Mar 4
Registration statement
S-3
Registration statement
Mar 3
Current report
8-K
Financial results
Mar 3
Annual report
10-K
FY2021, ended Dec 31
Annual report for FY2021
Revenue $1.16M
▼ 88.6%
Net loss $63.43M
Diluted EPS -$1.23
Jan 27
Current report
8-K
Events of Jan 21
Director or officer change, or executive pay, Other events
2021
Nov 2
Current report
8-K
Financial results
Nov 2
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $86.56K
▼ 91.3%
Net loss $17.33M
Aug 5
Current report
8-K
Events of Jul 30
Financial results, Director or officer change, or executive pay, Regulation FD disclosure, Other events
Aug 5
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $142
Net loss $14.4M
Showing 51–100 of 121 documents
Key facts
CIK
1253689
CUSIP
G2545C104
13F (30d)
102 filings
99 filers
Visit website
Investor relations